Colistimethate Sodium - Sino Biopharmaceutical/Chia Tai Tianqing Pharmaceutical Group
Alternative Names: TQD-3524Latest Information Update: 10 Apr 2026
At a glance
- Originator Sino Biopharmaceutical
- Developer Chia Tai Tianqing Pharmaceutical Group; Sino Biopharmaceutical
- Class Antibacterials; Polymixins; Small molecules
- Mechanism of Action Cell membrane modulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Gram-negative infections
Most Recent Events
- 30 Mar 2026 Chia Tai Tianqing Pharmaceutical Group plans a phase II trial for Nosocomial-pneumonia in China (IV) (NCT07512596)
- 18 Dec 2025 Chia Tai Tianqing Pharmaceutical Group completes a phase I trial for Gram-negative infections in China (Parenteral) (NCT06522945)
- 26 Jul 2024 Preclinical trials in Gram-negative infections in China (Parenteral)